Despite extensive research over several decades the pathomechanism(s) underlying Type I (insulin-dependent) diabetes mellitus have remained poorly defined. Also, the course of the destructive process in the pancreatic beta cells during the prodromal period is inadequately characterised. Animal models and studies on first-degree relatives of subjects with Type I diabetes have accumulated data on genetic, autoimmune and metabolic factors contributing to the disease process. Only about 10 % of the new patients have, however, a first-degree relative with Type I dia- Diabetologia (2000) 
betes [1, 2] , and therefore studies on healthy subjects representing the general population could provide essential information.
The course of the preclinical phase of the disease and the identification of potential predictive and preventive strategies in the general population are the current focus of research on Type I diabetes. Autoantibodies to various beta-cell antigens have proved to be an early marker of ongoing beta-cell destruction and are widely used to assess the risk of future manifestation of clinical disease in first-degree relatives of patients with Type I diabetes [3] . Similarly, a reduced early insulin response to intravenous glucose, reflecting impaired beta-cell function, is highly predictive for rapid progression to overt diabetes [4] .
We studied the stability of the autoantibody status over 2 years in 104 initially antibody-positive healthy schoolchildren and 104 antibody-negative control children matched for sex, age and place of residence. We also assessed the relations between disease-associated autoantibodies, genetic HLA-DQB1-risk markers and first-phase insulin response (FPIR). All subjects were monitored for progression to Type I diabetes over 3.4 years.
Subjects and methods
Subject and study design. A series of 104 antibody-positive healthy schoolchildren and 104 control children (matched for age, sex and place of residence) were recruited from the study on beta-cell autoimmunity in schoolchildren in northern Finland. The study was initiated at the beginning of 1994, when all 7 to 16-year-old schoolchildren (n = 4280) living in five municipalities in the Province of Oulu (Haapajärvi, Ii, Oulainen, Yli-Ii and Ylikiiminki) were invited to take part in the study. Informed consent was obtained from the subjects or their parents or both. The study design was approved by the ethics committee, Faculty of Medicine, University of Oulu. Of the subjects 17 (0.4 %) had clinical Type I diabetes at the time of recruitment for the study. Information on the HLA genotype was available in 15 of these children, out of whom 6 (40 %) were DQB1*02/0302 heterozygous, 4 (27 %) carried the DQB1*0302/x genotype (x other than *02, *0301 or *0602) and 3 (20 %) the DQB1*02/y genotype (y other than *0302, *0301 or *0602). One had the DQB1*0302/0602 genotype and one the DQB1*02/0301 genotype.
Serum samples were initially collected from 3662 subjects who gave their consent to take part in the study. Of these 10 were excluded as they already had previously diagnosed clinical diabetes. Altogether, 3652 non-diabetic schoolchildren (85.3 %) were included and all of them were initially analysed for islet cell antibodies (ICA) and for antibodies to the 65 000 M r isoform of glutamic acid decarboxylase (GADA). More recently all subjects were in addition tested for insulin autoantibodies (IAA) and antibodies to the protein tyrosine phosphatase-related IA-2 molecule (IA-2A). There were 106 subjects (2.9 %) who initially tested positive for ICA or GADA or both. Of these 104 and a further 104 control children negative for all four antibody specificities and matched for age, sex and place of residence, were invited to take part in the second part of the study. Two of the subjects who were initially positive for ICA or GADA or both were excluded because they progressed to Type I diabetes before the second part of the study. The second part of the study included blood sampling for autoantibody determinations (ICA, IA-2A, GADA and  IAA) , interview/questionnaire, physical examination and an intravenous glucose tolerance test (IVGTT). The group of autoantibody-positive children comprised 51 boys and 53 girls and their mean age at the time of the IVGTT was 13.7 years (range 9.4±18.8 years). Of the antibody positive subjects two had a first-degree relative with Type I diabetes (the father of one subject and the mother of the other subject). The subjects were asked whether and when they had had upper respiratory tract infections, gastroenteritis or other specific infections since the initial blood sampling and whether they had had symptoms associated with diabetes (thirst, excessive drinking, weight loss, tiredness). Physical examination included measurement of weight, height and waist:hip ratio. Relative weight (actual weight in relation to mean weight for height) was assessed based on Finnish growth charts [5] .
The children were observed for progression to Type I diabetes from the time of the second sampling to the end of May 1999 for a mean of 3.4 years (range 3.2±3.6 years) using the Central Drug Registry of the Social Insurance Institute, which has an ascertainment rate of more than 99 % for new patients with Type I diabetes (Reunanen A, personal communication).
Intravenous glucose tolerance tests. We successfully carried out IVGTTs in 103 antibody-positive (99 %) and 103 antibodynegative subjects (99 %) according to the ICARUS protocol [6] . After 10±16 h of fasting, 0.5 g/kg glucose in a 20 % solution was infused intravenously for 3 min ± 15 s. Blood samples were taken 5 and 0 min before the infusion and 1, 3, 5 and 10 min after the infusion had been completed. Serum insulin concentrations were measured with an enzyme-linked immunosorbent assay [7] . The sensitivity of the assay was 0.5 mU/l and the intra-assay and inter-assay coefficients of variation were less than 7.5 % and 9.3 %, respectively. Blood glucose concentrations were analysed with the glucose oxidase method [8] . The first-phase insulin response (FPIR) to glucose was defined as the sum of the 1-min and 3-min serum insulin concentrations.
Islet cell antibodies. We measured ICA by a standard immunofluorescence method using sections of frozen human group O pancreas [9] . All sera with detectable ICA were titrated to end-point dilution and the results were expressed in Juvenile Diabetes Foundation (JDF) units by comparison with an international standard reference serum [10] . The detection limit for ICA was 2.5 JDF units. Our laboratory had a sensitivity of 100 %, a specificity of 98 %, a validity of 98 % and a consistency of 98 % in the fourth round of the international workshops on standardization of the ICA assay [11] .
Antibodies to the IA-2 molecule. We analysed IA-2A with a radiobinding assay as described previously [11] . Briefly, the intracellular fragment of the IA-2 protein, including amino acids 605±979, was produced by in vitro transcription and translation in the presence of 35 S-methionine. Serum samples were incubated overnight with labelled IA-2 protein (10 000 cpm/well). Immunocomplexes were isolated using protein A sepharose (Pharmacia Biotech, Uppsala, Sweden). All the samples were tested in duplicate. The radioactivity was measured in a scintillation counter and the results are expressed in relative units (RU) based on a standard curve run on each plate. The cutoff limit for positivity (0.43 RU) was set at the 99th centile for 374 non-diabetic Finnish children and adolescents. The disease sensitivity of our assay was 62 % and the disease specificity 97 % based on 140 samples included in the Multiple Autoantibody Workshop [12] .
Antibodies to glutamic acid decarboxylase. We quantified GADA with a radiobinding assay as described previously [13] . Briefly, serum samples were incubated overnight with 35 S-methionine-labelled in vitro transcribed and translated human recombinant GAD 65 protein. All the samples were analysed in quadruplicate with and without an excess of unlabelled GAD 65 . Immunocomplexes were isolated using protein A sepharose (Pharmacia Biotech). The radioactivity was measured in a scintillation counter and the results are expressed in relative units (RU) representing the specific binding as a percentage of that obtained with a positive standard serum. The cut-off limit for GADA positivity was defined as 6.6 relative units (RU), representing the 99th centile in a series of 372 healthy control children. The disease sensitivity of this assay was 79 % and the disease specificity 97 %, based on the Multiple Autoantibody Workshop [12] .
Insulin autoantibodies. We analysed IAA with a radiobinding micro-assay, modified from that described previously [14] . The serum samples (5 ml) were incubated on 96-deep-well plates with mono 125 I-(TyrA14)-labelled human insulin. After incubation for 72 h, the immunocomplexes were precipitated using protein A sepharose. The volume of the incubation reaction was doubled by adding the reaction buffer [TBT; 50 mmol/l TRIS, pH 8.0, 1 % (v/v) Tween 20] . After washings with reaction buffer, the samples were transferred to microtitration plates, scintillation liquid was added and the bound activity was measured with a liquid scintillation counter (1450 MicroBeta Trilux; EG&G Wallac, Turku, Finland). If the total binding exceeded the 95th centile in 371 non-diabetic Finnish subjects, the sample was reanalysed in the presence or absence of unlabelled insulin and the specific binding was expressed in relative units (RU) based on a standard curve run on each plate using the MultiCalc software program (EG&G Wallac). The standard curve was constructed from nine serial dilutions of a serum from a patient with a high insulin antibody titre and a serum from an IAA-negative subject. The cut-off limit for IAA positivity was set at the 99th centile in the 371 non-diabetic subjects (1.56 RU). The performance characteristics of this assay were compared to that run in Bristol [14] based on a blinded sample exchange comprising 100 samples. There was a strong correlation between the two assays (r = 0.96; p < 0.001) and the concordance rate was 94 %. The disease sensitivity of our micro-assay was 35 % and the specificity 100 % based on 140 samples derived from the 1995 Multiple Autoantibody Workshop [12] .
Typing of HLA. We defined HLA-DQB1 alleles by a previously described method based on time-resolved fluorescence [15] . We used four sequence-specific oligonucleotide probes to identify the following DQB1 alleles known to be associated with either susceptibility to or protection against Type I diabetes in the Finnish population: DQB1*0302, DQB1*02, DQB1*0602 or 0603, and DQB1*0301 [16] . To differentiate between DQA1*05-DQB1*02 (DR3) and DQA1*0201-DQB1*02 (DR7) haplotypes all DQB1*02-positive samples were further analysed for the presence of the DQA1*05 or the DQA1*0201 allele [17] .
Statistical analyses. Student's t test was used to analyse normally distributed continuous variables and the Mann-Whitney U test and Kruskall-Wallis analysis in skewed distributions. Differences in the distribution of subjects between groups were tested with chi-squared statistics with Yates' correction unless any expected value was less than five, when Fisher's exact test was used [18] . Correlations between variables were tested with Spearman's non-parametric correlation analysis (r s ). A two-tailed p value of 0.05 or less was considered to indicate statistical significance. All the statistical analyses were done using the SPSS statistical software package for Windows, version 8.0 (SPSS, 1998, Chicago, Ill., USA).
Results
The stability of the antibody status. The distribution of the specific antibody combinations in initial and follow-up samples of 104 subjects initially positive for ICA and/or GADA is shown in Figure 1 . The mean time interval between the first and second serum samples was 1.9 years (range 1.7±2.2 years). Only 3 out of the 98 (3.1 %) subjects initially positive for ICA tested negative in the follow-up sample. All of them had low levels of ICA (4, 6 and 6 JDF units) in the first sample, and they were negative for the other autoantibodies on both occasions. Correspondingly, 3/13 (23.1 %) subjects initially positive for IA-2A turned negative for IA-2A and low initial levels of these antibodies also characterised them. They tested negative for GADA and IAA on both occasions but were positive for ICA with increasing levels over time. Only 1/17 (5.9 %) subjects initially positive for GADA turned negative for GADA in the follow-up sample. This boy had relatively high levels of GADA (56. There was a positive correlation between ICA and IA-2A levels in subjects testing positive for both of these antibodies in their initial blood sample (n = 11) (r s = 0.77, p = 0.006) but not between the levels of ICA and GADA among subjects positive for both of these antibodies (n = 11) (r s = 0.36, p = 0.29).
Autoantibodies and clinical characteristics. The children with IA-2A were younger than those with other antibodies (p = 0.002, data not shown) or the control children (p = 0.012, Table 1 ). Similarly, the children with multiple antibodies were younger than the subjects positive for one antibody only (p = 0.018, data not shown) or the control children (p = 0.019, Table 1). Relative body weight or waist:hip ratio did not differ between the control subjects and the subjects with any antibody (one or more), multiple antibodies (two or more) or those positive for any specific antibody.
Relation between first-phase insulin response, autoantibodies and HLA-DQB1 risk markers. The FPIRs did not differ significantly between the antibody positive subjects and control children (Fig. 2, Table 2) . Similarly, the FPIRs did not differ significantly between the ICA-positive and control children (Fig. 2,  Table 2 ), even if only those with an ICA level of 10 (Fig. 2, Table 2 ). The median FPIR in those 11 children with single antibody positivity to a biochemically characterised antigen, irrespective of ICA status, was 77 mU/l (IQR 58±109 mU/l) which was lower, although not significantly so (p = 0.158), than that seen in the control children (median 92 mU/l, IQR 71±125 mU/I). No significant correlation between age and FPIR either among the antibody-positive children or among the control children was observed (r s = 0.074 and 0.124, respectively).
There were no significant differences in the FPIR between subjects with and without the DQB1*02, DQB1*0302, DQB1*0301 or DQB1*0602±3 allele nor between those with and without the DQB1*02/ *0302, DQB1*0302/x or DQB1*02/x (ªxº indicates unrecognised allele or homozygosity for a marked allele) genotype (data not shown). These results remained non-significant irrespective of whether the control subjects were or were not included in the analysis.
Altogether, six (5.8 %) initially antibody-positive subjects had a FPIR value below the 1st centile of the FPIR values seen in the control children ( < 29.5 mU/l) (Fig. 2.) . The characteristics of these children are shown in Table 3 . Of these three tested positive for one antibody specificity and one for two antibodies in both samples. The two remaining subjects had three or four antibodies on both occasions. None of these six children had a DQB1 genotype associated with increased risk for progression to Type I diabetes, whereas three of them carried the DQB1*0602 or *0603 allele conferring decreased risk.
Progression to Type I diabetes. Two children have progressed to clinical diabetes ( Table 3 No chronic disorders were reported other than allergy to citrus fruits in the second subject. Both children had had a non-specific upper respiratory tract infection and the first subject also had acute otitis media between the two examinations. He carried the DQB1*0301/*0603 genotype whereas the second subject had the DQB1*02/ *0602 genotype (the DQA1*05-DQB1*02 haplotype).
Discussion
Data on aetiological factors and the course of the destruction of pancreatic beta cells are essential to resolve the pathomechanisms of Type I diabetes. Whether the autoimmune destructive process always leads to clinical disease and whether this process is similar in all people (e. g. in first-degree relatives and in the general population) is not known. Our study further explains the course of beta-cell autoimmunity in healthy children representing the general population and provides valuable data on the relations between humoral, genetic and metabolic markers in such subjects.
The natural course of humoral autoimmunity, i. e. changes in positivity and quantity of autoantibodies, has mainly been studied in first-degree relatives of patients with Type I diabetes [19±32] . These studies have shown fluctuations in the antibody levels and seroconversions from antibody positivity to antibody negativity and vice versa during the follow-up. In general, antibody positivity seems to be a rather stable phenomenon at least in older children because antibodies disappear only in a few subjects even during a long follow-up period [22, 28, 29] . Seroconversion to antibody negativity has been shown to be associated with low titre of antibodies and single antibody positivity [25, 29] , whereas stable antibodies are more often associated with high titres and the presence of multiple antibodies [28, 29, 31] . Whether these findings are also valid in the general population is not well documented for the various antibody specificities. The reported proportions of initially ICApositive subjects turning ICA-negative during follow-up among the general population have varied from 14 % to 78 % [33±37]. One group studied 2908 healthy schoolchildren and had follow-up samples from 55 initially ICA-positive subjects. Of these 17 (31 %) were ICA-negative in their second sample taken 7±14 months after the first sample and most of those who seroconverted had low initial levels of ICA [37] . One study has reported fluctuation in the titre and positivity of GADA in subjects with a negative family history for Type I diabetes [38] and seroconversion from IAA positivity to IAA negativity was reported in some French schoolchildren [28] . Results from our study confirm that all individual markers of humoral islet autoimmunity can fluctuate during prospective follow-up including those in healthy schoolchildren. In the majority of subjects, however, the antibody status remained stable and e. g. seroconversion to ICA negativity was relatively rare and usually associated with low titres and positivity for ICA only.
There is only scanty data on the relations between autoantibodies and demographic characteristics in people with signs of preclinical diabetes representing the general population. A higher frequency of GADA in non-diabetic schoolchildren over 10 years of age than in those under this age and a male predominance of these antibodies has been reported [39] . In the same study, IAA was associated with young age, whereas ICA and IA-2A did not vary with age or sex. Another study reported normal body mass indexes in 40 ICA-positive healthy schoolchildren [35] . In our series of unaffected schoolchildren, we could not find any relation between clinical characteristics and the presence of autoantibodies, with the exception of an association between young age and IA-2A and multiple antibodies.
Several studies have reported decreased FPIR to intravenous glucose in ICA-positive, first-degree relatives of patients with Type I diabetes [40, 41] . Recently, a strong correlation between the presence of GADA and low FPIR was reported [42] . In that study, there were also 13 subjects with multiple antibodies in the initial screening without signs of impaired beta-cell function. Only a limited number of studies have been published reporting relations between autoantibodies and FPIR in the general population. In a study of 40 ICA-positive schoolchildren 2 subjects had a low FPIR [35] . These subjects had high titres of ICA and also tested positive for GADA and IAA. In addition, one subject was initially positive for complement-fixing ICA and GADA and FPIR decreased under the 1st centile after 6 months of follow-up. In a recent German study, 60 % (10/17) of schoolchildren with multiple antibodies were reported to have a decreased FPIR after 4±16 months of follow-up [43] . In our study a reduced FPIR was observed in children with IA-2A, GADA, IAA, or multiple antibodies. There was, however, a substantial overlapping of children between the groups testing positive for IA-2A, GADA or IAA and those with multiple antibodies. This indicates that a decreased FPIR is primarily associated with positivity for multiple antibodies, although the IAApositive children among those with multiple antibodies had the lowest FPIR median. Our observation confirms that humoral autoimmunity against betacell antigens reflects impaired beta-cell function and probably an ongoing destruction of the insulin-producing cells.
Genetic determinants of FPIR are poorly defined. One study has reported a reduced insulin response to i. v. glucose in HLA-identical siblings of patients with Type I diabetes [44] whereas another study failed to show any relation between the degree of HLA identity or HLA class II antigens and the early insulin response [45] . We have previously reported an association between a reduced FPIR and HLArisk markers in siblings of children with Type I diabetes [46] . In the present study on healthy schoolchildren, we did not, however, observe any relation between HLA-DQB1-risk alleles or genotypes and FPIR, irrespective of the antibody status. These observations could reflect differences in the genetic background or in the disease process itself between siblings of children with Type I diabetes and healthy non-selected schoolchildren. Family members could carry additional susceptibility genes which have an epistatic effect with HLA genes on the disease process and therefore decreased FPIRs are found to be associated with HLA markers among siblings, but not necessarily in the general population.
Neither of the two children who progressed to clinical diabetes in our study had an HLA-DQB1 genotype shown to be associated with increased risk for Type I diabetes nor the DQB1*0302 allele conferring the strongest disease susceptibility. In contrast, both of them carried the DQB1*0602 or *0603 allele that has been observed to be associated with a decreased susceptibility for Type I diabetes. Thus, these two children would not have been identified on the basis of HLA-DQB1-risk markers but should have been classified as subjects with a decreased genetic risk. In contrast, on the basis of humoral or metabolic markers or both they would have been identified correctly as high-risk subjects.
Both earlier studies and the distribution of HLA alleles in the previously diagnosed children in the present study region show HLA-DQB1*0302 and DQB1*02 to be the strongest susceptibility alleles for Type I diabetes among Finnish children [16, 47] . Thus the lack of any apparent association between these genetic risk markers and FPIR or progression to overt diabetes in the present series is unexpected. The number of children with a reduced FPIR and of those who presented with clinical disease is, however, low which limits the interpretation of the data. On the other hand, we have previously observed a higher frequency of protective DQB1 alleles among children diagnosed with Type I diabetes at an age older than 5 years than in those diagnosed at a younger age [48] . This might contribute to the present results because all schoolchildren were older than 9 years when tested for their FPIR or diagnosed with Type I diabetes.
We show that the presence of autoantibodies against specific beta-cell antigens is usually a stable phenomenon in unaffected schoolchildren, particularly in those with multiple antibodies, although any of these markers can occasionally disappear during follow-up. We also observed that a reduced early insulin response was related to autoantibodies but not to the HLA-DQB1-risk markers in this series of non-diabetic children over the age of 9 years. Our observations suggest in addition that the DQB1 alleles conferring decreased disease susceptibility do not provide protection from strong humoral beta-cell autoimmunity, deterioration of the beta-cell function or from progression to overt Type I diabetes in initially unaffected schoolchildren representing the general population.
